Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $1.4 billion.

  • Agios Pharmaceuticals' Liabilities and Shareholders Equity fell 2266.38% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 billion, marking a year-over-year increase of 3961.63%. This contributed to the annual value of $1.7 billion for FY2024, which is 7748.02% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $1.4 billion for Q3 2025, which was down 2266.38% from $1.5 billion recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $2.5 billion in Q1 2021 and a low of $773.1 million during Q2 2024
  • Over the past 5 years, Agios Pharmaceuticals' median Liabilities and Shareholders Equity value was $1.3 billion (recorded in 2022), while the average stood at $1.4 billion.
  • In the last 5 years, Agios Pharmaceuticals' Liabilities and Shareholders Equity soared by 21115.62% in 2021 and then crashed by 4631.73% in 2022.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.4 billion in 2021, then fell by 13.84% to $1.2 billion in 2022, then dropped by 24.35% to $937.1 million in 2023, then soared by 77.48% to $1.7 billion in 2024, then decreased by 16.68% to $1.4 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.4 billion for Q3 2025, versus $1.5 billion for Q2 2025 and $1.6 billion for Q1 2025.